Martin Auster

BioMarin Shares Slammed After Hemophilia A Gene Therapy Stumbles At FDA

Acceleron Hits All-Time High On Positive Readout For Pulmonary Arterial Hypertension Drug

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Acceleron Hits All-Time High On Positive Readout For Pulmonary Arterial Hypertension Drug

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

FDA Approves Sarepta's Second DMD Drug, Analyst Projects $500M-Plus Opportunity

Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy

FDA Approves Sarepta's Second DMD Drug, Analyst Projects $500M-Plus Opportunity

Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy

Credit Suisse: United Therapeutics Becoming More Fundamentally Driven

6 Gene Therapy M&A Targets On The Radar

Martin Auster Recent News

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Credit Suisse Joins Consensus To Prescribe Sarepta

Insmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade

United Therapeutics Has Limited Downside Below $95 Level, Credit Suisse Says In Upgrade

Credit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed Trial

The Key To Alexion's Long-Term Upside Potential, According To Credit Suisse

Alexion's New CFO Continues To Shore Up Investor Concerns

Analyst: With This Much Pessimism Priced In, Alexion Begins To Look Attractive